{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009686","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.962599+00:00","generated_at":"2026-06-04T06:13:39.199812+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Monopar reports Q4/FY2023 net loss of $1.8M/$8.4M; MNPR-101 Phase 1 dosimetry trial to start","bullets":["Cash, equivalents and short-term investments $7.3M at Dec. 31, 2023; plus $3.2M from Q1 2024 ATM; runway through June 30, 2025.","Net loss Q4 2023: $1.8M ($0.12/shr) vs $2.9M ($0.22/shr) in Q4 2022; FY 2023: $8.4M ($0.61/shr) vs $10.5M ($0.83/shr) in FY 2022.","R&D expenses fell to $1.0M in Q4 2023 ($2.1M Q4 2022) and $5.6M for FY 2023 ($7.6M FY 2022), driven by Validive cost reductions.","MNPR-101-Zr Phase 1 dosimetry trial cleared by HREC in Australia; lead investigator Professor Rodney Hicks; enrollment imminent.","Preclinical data: MNPR-101-Ac-225 caused near-complete tumor elimination in triple-negative breast xenograft model after single dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009686","json":"https://secwatch.observer/filing/0001437749-24-009686.json","markdown":"https://secwatch.observer/filing/0001437749-24-009686.md","text":"https://secwatch.observer/filing/0001437749-24-009686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/0001437749-24-009686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/mnpr20240325_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:13:39.199812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7f8ccf62d861979365e1473cec93e5cc1f10050","claim":"Monopar Therapeutics reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share.","evidence_excerpt":"Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/0001437749-24-009686-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}